160 related articles for article (PubMed ID: 34137053)
1. Efficacy and safety in the treatment of hyperprolactinemia: A systematic review and network meta-analysis.
Fachi MM; de Deus Bueno L; de Oliveira DC; da Silva LL; Bonetti AF
J Clin Pharm Ther; 2021 Dec; 46(6):1549-1556. PubMed ID: 34137053
[TBL] [Abstract][Full Text] [Related]
2. Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.
Chen H; Fu J; Huang W
Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008883. PubMed ID: 27455388
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of quinagolide in hyperprolactinemia treatment: A systematic review and meta-analysis.
Zeng Y; Huang Q; Zou Y; Tan J; Zhou W; Li M
Front Endocrinol (Lausanne); 2023; 14():1027905. PubMed ID: 36761195
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline versus bromocriptine in the treatment of hyperprolactinemia: a systematic review of randomized controlled trials and meta-analysis.
dos Santos Nunes V; El Dib R; Boguszewski CL; Nogueira CR
Pituitary; 2011 Sep; 14(3):259-65. PubMed ID: 21221817
[TBL] [Abstract][Full Text] [Related]
5. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients.
Giusti M; Porcella E; Carraro A; Cuttica M; Valenti S; Giordano G
J Endocrinol Invest; 1994 Jan; 17(1):51-7. PubMed ID: 7911813
[TBL] [Abstract][Full Text] [Related]
6. Hyperprolactinemia: pathophysiology and management.
Verhelst J; Abs R
Treat Endocrinol; 2003; 2(1):23-32. PubMed ID: 15871552
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline and hyperprolactinaemia: new preparation. Better than bromocriptine.
Prescrire Int; 2000 Feb; 9(45):195-7. PubMed ID: 11503793
[TBL] [Abstract][Full Text] [Related]
9. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients.
De Luis DA; Becerra A; Lahera M; Botella JI; Valero ; Varela C
J Endocrinol Invest; 2000; 23(7):428-34. PubMed ID: 11005266
[TBL] [Abstract][Full Text] [Related]
10. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.
Webster J
Drug Saf; 1996 Apr; 14(4):228-38. PubMed ID: 8713691
[TBL] [Abstract][Full Text] [Related]
11. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst J; Abs R; Maiter D; van den Bruel A; Vandeweghe M; Velkeniers B; Mockel J; Lamberigts G; Petrossians P; Coremans P; Mahler C; Stevenaert A; Verlooy J; Raftopoulos C; Beckers A
J Clin Endocrinol Metab; 1999 Jul; 84(7):2518-22. PubMed ID: 10404830
[TBL] [Abstract][Full Text] [Related]
12. Current drug withdrawal strategy in prolactinoma patients treated with cabergoline: a systematic review and meta-analysis.
Hu J; Zheng X; Zhang W; Yang H
Pituitary; 2015 Oct; 18(5):745-51. PubMed ID: 25500765
[TBL] [Abstract][Full Text] [Related]
13. Dopamine agonist therapy in hyperprolactinemia.
Webster J
J Reprod Med; 1999 Dec; 44(12 Suppl):1105-10. PubMed ID: 10649819
[TBL] [Abstract][Full Text] [Related]
14. Prolactin excess: treatment and toxicity.
Gillam MP; Fideleff H; Boquete HR; Molitch ME
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():108-14. PubMed ID: 16456489
[TBL] [Abstract][Full Text] [Related]
15. Retrospective comparison of cabergoline and bromocriptine effects in hyperprolactinemia: a single center experience.
Arduc A; Gokay F; Isik S; Ozuguz U; Akbaba G; Tutuncu Y; Berker D; Kucukler FK; Aydin Y; Guler S
J Endocrinol Invest; 2015 Apr; 38(4):447-53. PubMed ID: 25421155
[TBL] [Abstract][Full Text] [Related]
16. Dopamine agonists for preventing ovarian hyperstimulation syndrome.
Tang H; Mourad S; Zhai SD; Hart RJ
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD008605. PubMed ID: 27901279
[TBL] [Abstract][Full Text] [Related]
17. Quinagolide--a valuable treatment option for hyperprolactinaemia.
Barlier A; Jaquet P
Eur J Endocrinol; 2006 Feb; 154(2):187-95. PubMed ID: 16452531
[TBL] [Abstract][Full Text] [Related]
18. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
19. Management of borderline hyperprolactinemia.
del Pozo E
Horm Res; 1985; 22(3):204-8. PubMed ID: 4054840
[TBL] [Abstract][Full Text] [Related]
20. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine.
De Rosa M; Colao A; Di Sarno A; Ferone D; Landi ML; Zarrilli S; Paesano L; Merola B; Lombardi G
Eur J Endocrinol; 1998 Mar; 138(3):286-93. PubMed ID: 9539303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
